KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLong-Term Debt RepaymentsR&D In ProcessShort-Term Debt issuancesShort-Term Debt repayments
Ratios

Pfizer (PFE) Accumulated Depreciation & Amortization (2016 - 2025)

Historic Accumulated Depreciation & Amortization for Pfizer (PFE) over the last 17 years, with Q3 2025 value amounting to $1.7 billion.

  • Pfizer's Accumulated Depreciation & Amortization fell 529.91% to $1.7 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 billion, marking a year-over-year decrease of 529.91%. This contributed to the annual value of $7.0 billion for FY2024, which is 1149.44% up from last year.
  • According to the latest figures from Q3 2025, Pfizer's Accumulated Depreciation & Amortization is $1.7 billion, which was down 529.91% from $1.6 billion recorded in Q2 2025.
  • Over the past 5 years, Pfizer's Accumulated Depreciation & Amortization peaked at $7.0 billion during Q4 2024, and registered a low of $1.5 billion during Q2 2023.
  • Over the past 5 years, Pfizer's median Accumulated Depreciation & Amortization value was $2.4 billion (recorded in 2022), while the average stood at $3.3 billion.
  • As far as peak fluctuations go, Pfizer's Accumulated Depreciation & Amortization surged by 3032.44% in 2023, and later plummeted by 6201.3% in 2024.
  • Over the past 5 years, Pfizer's Accumulated Depreciation & Amortization (Quarter) stood at $5.2 billion in 2021, then dropped by 2.45% to $5.1 billion in 2022, then grew by 24.21% to $6.3 billion in 2023, then increased by 11.49% to $7.0 billion in 2024, then tumbled by 76.3% to $1.7 billion in 2025.
  • Its last three reported values are $1.7 billion in Q3 2025, $1.6 billion for Q2 2025, and $1.6 billion during Q1 2025.